Seliciclib Roscovitine Cdk Inhibitors
| Product name:Roscovitine seliciclib | Purity:98% min |
| CAS NO:186692-46-6 | Solubility:DMSO : ≥ 100 mg/mL (282.13 mM) |
| Molecular Formula:C19H26N6O | Package:Package according to customer requirements |
| Molecular Weight:354.449 | Storage:Store at -20℃ |
Seliciclib, also known as roscovitine and CYC202, is a n orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Seliciclib primarily inhibits CDK2/E, CDK2/A, CDK7 and CDK9 by competing for their ATP binding sites, leading to a disruption of cell cycle progression. In addition, this agent appears to interfere with CDK-mediated phosphorylation of the carboxy-terminal domain of RNA polymerase II, inhibiting RNA polymerase II-dependent transcription, which may result in the down-regulation of antiapoptotic proteins such as induced myeloid leukemia cell differentiation protein Mcl-1.
Related Products:
Flavopiridol HCL; Flavopiridol; THZ1; BMS-863233 HCl; Dinaciclib; AZD5438; Palbociclib Isethionate; PHA-793887; RO-3306; Abemaciclib mesylate; Abemaciclib; JNJ-7706621
[1] Meijer L, et al. Eur J Biochem, 1997, 243(1-2), 527-536.
[2] Pippin JW, et al. J Clin Invest, 1997, 100(10), 2512-2520.
[3] Huber RJ, et al. J Cell Biochem, 2012, 113(3), 868-876.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.